Holen Sie sich die Stockscreener-App
1.63
3.16%
0.05
Schlusskurs vom Vortag:
$1.58
Offen:
$1.58
24-Stunden-Volumen:
4.57M
Relative Volume:
1.12
Marktkapitalisierung:
$432.55M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-5.8214
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
+3.82%
1M Leistung:
-2.40%
6M Leistung:
-58.42%
1J Leistung:
-17.68%
1-Tages-Spanne:
$1.56
$1.63
1-Wochen-Bereich:
$1.53
$1.63
52-Wochen-Spanne:
$1.445
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.63 | 419.28M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
118.07 | 51.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.37 | 45.05B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.46 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.80 | 32.77B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.86 | 20.51B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Why Akebia Therapeutics Inc AX9 stock attracts HNW investorsPortfolio Return Report & Reliable Entry Point Alerts - BỘ NỘI VỤ
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Will Akebia Therapeutics Inc. (AX9) stock sustain dividend payoutsNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - MSN
Is Akebia Therapeutics Inc. (AX9) stock testing key support2025 Key Highlights & Free Real-Time Volume Trigger Notifications - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Akebia Therapeutics, Inc. (AKBA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Pfizer-backed biotech lands $120M, plus other Boston-area life science news - The Business Journals
With Akebia Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights
Akebia Therapeutics (NASDAQ:AKBA) Receives Buy Rating from BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Why Akebia Therapeutics Inc. (AX9) stock could be top winnerQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser
Akebia Therapeutics announces establishment of rare kidney disease pipeline - MSN
HC Wainwright & Co. Reiterates Akebia Therapeutics (AKBA) Buy Recommendation - MSN
BTIG Reiterates Buy Rating for Akebia Therapeutics (AKBA) | AKBA Stock News - GuruFocus
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here? - Yahoo Finance
Akebia Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
HC Wainwright & Co. Reiterates Buy Rating for AKBA, Price Target Unchanged | AKBA Stock News - GuruFocus
QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget
Is Akebia Therapeutics Inc a good long term investmentStock Market Trends & Access Free Tools and Start Investing - earlytimes.in
Can Akebia Therapeutics Inc. (AX9) stock sustain revenue momentumEarnings Overview Summary & Low Risk High Reward Ideas - Newser
Is Akebia Therapeutics Inc. (AX9) stock protected from inflationTrade Volume Report & Free Technical Confirmation Trade Alerts - Newser
Cyclerion Receives Milestone Payment from Akebia - TipRanks
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics (Nasdaq: AKBA) announces 22,576-share inducement grant - Stock Titan
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - ts2.tech
Q32 sells rare kidney disease drug to Akebia for $12M up front - BioWorld MedTech
Q32 Bio skyrockets as it sells complement inhibitor ADX-097 - The Pharma Letter
Akebia Therapeutics, Inc. Announces Establishment of Rare Kidney Disease Pipeline - marketscreener.com
Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - Benzinga
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - marketscreener.com
Q32 Bio stock rockets after selling Phase 2 complement inhibitor to Akebia - Investing.com Nigeria
Akebia announces establishment of rare kidney disease pipeline - marketscreener.com
Q32 Bio Sells Complement Inhibitor ADX-097 - citybiz
Akebia Therapeutics (AKBA) Expands Pipeline with Rare Kidney Dis - GuruFocus
Akebia Therapeutics (AKBA) Acquires Phase 2 Drug from Q32 Bio - GuruFocus
Akebia Therapeutics (AKBA) Acquires Phase 2 Inhibitor ADX-097 - GuruFocus
Q32 Bio sells complement inhibitor ADX-097 to Akebia - TipRanks
Akebia Therapeutics Acquires Global Rights to ADX-097 - TipRanks
Q32 Bio Sells ADX-097 to Akebia Therapeutics - TipRanks
Akebia Announces Establishment of Rare Kidney Disease Pipeline - The Manila Times
Akebia Therapeutics Establishes Rare Kidney Disease Pipeline with Acquisition of AKB-097 and Initiation of Praliciguat Phase 2 Trial - Quiver Quantitative
Akebia Therapeutics (Nasdaq: AKBA) acquires AKB-097, targets 2026 Phase 2 basket trial - Stock Titan
Geode Capital Management LLC Acquires 1,043,718 Shares of Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics, Inc. Initiates Phase 2 Clinical Trials for the Treatment of Focused Segmental Glomerulosclerosis Using Praliciguat - marketscreener.com
Is Akebia Therapeutics Inc. stock a buy on dips2025 Volume Leaders & Free Safe Capital Growth Stock Tips - BỘ NỘI VỤ
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Why analysts recommend Akebia Therapeutics Inc. (AX9) stockQuarterly Portfolio Review & Weekly Momentum Stock Picks - BỘ NỘI VỤ
Why Akebia Therapeutics Inc. stock is a must watch in 2025Quarterly Growth Report & Real-Time Volume Spike Alerts - moha.gov.vn
Is Akebia Therapeutics Inc. (AX9) stock a top pick for value investors2025 Risk Factors & Weekly High Momentum Picks - BỘ NỘI VỤ
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.87%
4.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):